01.06.2012 - Cancer diagnostics specialist Agendia NV closed a $65m private round of equity financing.
Amsterdam – The Dutch company will use the funds to expand commercialisation of their current breast cancer suite of tests, as well as for development of the personalised medicine pipeline, announced CEO David Macdonald. „The support we have received in this round of financing is a strong reflection of our recent growth and confidence in the commercialisation of our product pipeline in the future“, he added.
The financing round was led by the Swiss drug development company Debiopharm Group, with significant support from all of Agendia's current investors, including The Van Herk Group, ING Corporate Investments, Breedinvest and Gilde Healthcare. Korys, the Colruyt family office, was among the new investors.
Agendia's Symphony suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast tumour biology It is currently on the market in the US and Europe and includes several staging, subtyping, recurrence and therapy selection assays. Together, these tests might help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods. „Agendia will support genuine win-win strategies and facilitate the reduction of the gap between the diagnostic and the drug world," said Thierry Mauvernay, Delegate of the Board of Debiopharm.
Agendia was founded in 2003 as a spin-off from The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital in Amsterdam, for the purposes of pursuing commercialisation of molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.